Welcome to our dedicated page for Insight Molecular Diagnostics SEC filings (Ticker: IMDX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Insight Molecular Diagnostics Inc.'s SEC filings document a molecular diagnostics issuer developing donor-derived cell-free DNA assays for transplant monitoring. Current reports and proxy materials cover operating results, GraftAssure product disclosures, regulatory and clinical-development updates, investor-presentation materials, and capital-structure matters tied to financing and equity compensation.
Its filings also describe governance subjects including shareholder voting provisions, bylaws, board and executive compensation matters, equity incentive plan awards, and material agreements for specimen collection services related to GraftAssureCore testing.
Insight Molecular Diagnostics (IMDX) filed a Form 4/A reporting that its Chief Financial Officer, Andrea James, had 50,000 shares of common stock issued at $0 upon vesting of performance-based RSUs on 10/31/2025. To cover taxes, 12,175 shares were withheld at $6.01; no shares were sold. Following these transactions, she directly beneficially owned 189,056 shares.
The RSUs vested after the company’s public float reached at least $75 million, satisfying a “Baby Shelf” condition that ended Form S-3 “baby shelf” limitations. This amendment corrects the original report to include the tax withholding.
Insight Molecular Diagnostics (IMDX) filed its Q3 2025 10‑Q, reporting net revenue of $260K versus $115K a year ago and a net loss of $10.9M versus $13.5M. Gross profit was $139K as operating expenses reached $11.2M, including R&D of $3.9M and sales and marketing of $1.4M.
For the nine months, revenue was $2.916M versus $395K last year, with a net loss of $27.3M. Operating cash use was $16.6M. The balance sheet showed cash and cash equivalents of $18.7M, total assets of $43.9M, total liabilities of $53.1M, and a shareholders’ deficit of $9.2M.
Management evaluated going concern and concluded it will have sufficient cash for at least the next 12 months, aided by cost controls and the February 2025 offering that raised $29.1M gross (net proceeds ~$28.7M). Commercial progress included Medicare coverage and a $2,753 per‑result reimbursement for GraftAssureCore and initial RUO kit sales under the Bio‑Rad partnership. Common shares outstanding were 28,664,437 as of November 3, 2025.
Insight Molecular Diagnostics Inc. (IMDX) furnished an 8‑K to announce that it issued a press release with financial results for the three and nine months ended September 30, 2025. The press release is attached as Exhibit 99.1 and incorporated by reference. The Company noted that the information provided under Item 2.02, including Exhibit 99.1, is being furnished and not filed under the Exchange Act, and therefore is not subject to Section 18 liabilities, nor automatically incorporated into other filings except as specifically referenced. IMDX’s common stock trades on The Nasdaq Stock Market LLC under the symbol IMDX.
Insight Molecular Diagnostics (IMDX) reported an insider equity change: the CFO acquired 50,000 shares of Common Stock on 10/31/2025 via the vesting and settlement of performance-based RSUs at a stated price of $0. The vesting was triggered when the company’s public float reached at least $75 million, satisfying the “Baby Shelf” performance condition tied to Form S-3 eligibility.
Following the transaction, the reporting person beneficially owned 201,231 Common shares directly. The RSUs were granted under the company’s 2018 Equity Incentive Plan, with each RSU representing the right to receive one share upon settlement. The filing notes that this milestone resulted in the vesting of 50% of the RSUs granted to the reporting person, subject to continued service.
Insight Molecular Diagnostics Inc. reported new equity awards and a contract change for key executives. On September 28, 2025, the board granted stock options under the Amended and Restated 2018 Equity Incentive Plan to several leaders. Josh Riggs, President and CEO, received options to purchase 400,000 shares of common stock. Andrea James, CFO, and Dr. Ekkehard Schütz, Chief Science Officer, each received options for 235,000 shares, and James Liu, Vice President Accounting, Controller, Treasurer and Principal Accounting Officer, received options for 18,000 shares.
All options have an exercise price of $3.33 per share and vest over three years, with one-third vesting on the first anniversary and the remainder vesting in equal monthly installments over the following two years, subject to continued service. On September 29, 2025, the company also amended Dr. Schütz’s employment agreement so that his term continues until it is terminated in accordance with that agreement, rather than ending on a fixed four-year term.
Insight Molecular Diagnostics Inc. insider report: The company's Chief Financial Officer was granted an option to purchase 235,000 shares of common stock with an exercise price of $3.33 per share. The option was granted on 09/28/2025 and expires on 09/28/2035. Following the grant the reporting person beneficially owns 235,000 underlying shares, held directly. The option vests with 33 1/3% becoming exercisable after one year of continuous service from the grant date and the remaining balance vesting in 24 equal monthly installments thereafter, subject to continued service.
Insight Molecular Diagnostics reporting person Josh Riggs, who is listed as CEO and President and a director, acquired an option to purchase 400,000 shares of common stock on 09/28/2025. The option has an exercise price of $3.33 per share and an expiration date of 09/28/2035. The filing shows the reporting person directly beneficially owns the 400,000 option shares following the transaction. Vesting: 33 1/3% becomes exercisable after one year of continuous service from the grant date, with the remainder vesting in 24 equal monthly installments thereafter, subject to continued service. The Form 4 is signed by Josh Riggs on 09/30/2025.
Insight Molecular Diagnostics Inc. reported that its Board of Directors and Compensation Committee approved increases to the annual base salaries of two senior executives. Effective September 15, 2025, the annual base salary of President and Chief Executive Officer Joshua Riggs rose from $420,000 to $520,000, and the annual base salary of Chief Financial Officer Andrea James increased from $341,250 to $441,250. These changes reflect updated compensation levels for the company’s top leadership.
Insight Molecular Diagnostics Inc. reported that its Board of Directors and Compensation Committee approved increases to the annual base salaries of two senior executives. Effective September 15, 2025, the annual base salary of President and Chief Executive Officer Joshua Riggs rose from $420,000 to $520,000, and the annual base salary of Chief Financial Officer Andrea James increased from $341,250 to $441,250. These changes reflect updated compensation levels for the company’s top leadership.